vs
IBEX Ltd（IBEX）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是IBEX Ltd的1.2倍（$197.9M vs $164.2M），IBEX Ltd净利率更高（7.4% vs 6.7%，领先0.7%），IBEX Ltd同比增速更快（16.7% vs 13.6%），REPLIGEN CORP自由现金流更多（$17.6M vs $-5.1M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 13.8%）
IBEX 35是西班牙主要交易所马德里证券交易所的基准股票指数，该指数始创于1992年，由西班牙证券市场集团BME旗下的交易所公司负责计算与管理。它以市值加权编制，涵盖马德里证券交易所流动性最高的35只西班牙股票，每年进行两次成分股调整。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
IBEX vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.2倍
$164.2M
营收增速更快
IBEX
高出3.1%
13.6%
净利率更高
IBEX
高出0.7%
6.7%
自由现金流更多
RGEN
多$22.6M
$-5.1M
两年增速更快
RGEN
近两年复合增速
13.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.2M | $197.9M |
| 净利润 | $12.2M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 9.3% | 9.0% |
| 净利率 | 7.4% | 6.7% |
| 营收同比 | 16.7% | 13.6% |
| 净利润同比 | 31.8% | 143.9% |
| 每股收益（稀释后） | $0.83 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBEXRGEN
| Q4 25 | $164.2M | $197.9M | ||
| Q3 25 | $151.2M | $188.8M | ||
| Q2 25 | $147.1M | $182.4M | ||
| Q1 25 | $140.7M | $169.2M | ||
| Q4 24 | $140.7M | $174.1M | ||
| Q3 24 | $129.7M | $154.9M | ||
| Q2 24 | $124.5M | $154.1M | ||
| Q1 24 | $126.8M | $151.3M |
净利润IBEXRGEN
| Q4 25 | $12.2M | $13.3M | ||
| Q3 25 | $12.0M | $14.9M | ||
| Q2 25 | $9.6M | $14.9M | ||
| Q1 25 | $10.5M | $5.8M | ||
| Q4 24 | $9.3M | $-30.3M | ||
| Q3 24 | $7.5M | $-654.0K | ||
| Q2 24 | $9.8M | $3.3M | ||
| Q1 24 | $10.3M | $2.1M |
毛利率IBEXRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率IBEXRGEN
| Q4 25 | 9.3% | 9.0% | ||
| Q3 25 | 9.1% | 8.9% | ||
| Q2 25 | 8.3% | 7.6% | ||
| Q1 25 | 9.5% | 3.9% | ||
| Q4 24 | 8.5% | -17.7% | ||
| Q3 24 | 7.0% | -5.1% | ||
| Q2 24 | 10.3% | 1.0% | ||
| Q1 24 | 8.9% | 1.3% |
净利率IBEXRGEN
| Q4 25 | 7.4% | 6.7% | ||
| Q3 25 | 8.0% | 7.9% | ||
| Q2 25 | 6.5% | 8.2% | ||
| Q1 25 | 7.4% | 3.4% | ||
| Q4 24 | 6.6% | -17.4% | ||
| Q3 24 | 5.8% | -0.4% | ||
| Q2 24 | 7.9% | 2.2% | ||
| Q1 24 | 8.1% | 1.4% |
每股收益（稀释后）IBEXRGEN
| Q4 25 | $0.83 | $0.24 | ||
| Q3 25 | $0.82 | $0.26 | ||
| Q2 25 | $0.63 | $0.26 | ||
| Q1 25 | $0.73 | $0.10 | ||
| Q4 24 | $0.57 | $-0.55 | ||
| Q3 24 | $0.43 | $-0.01 | ||
| Q2 24 | $0.55 | $0.06 | ||
| Q1 24 | $0.57 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $767.6M |
| 总债务越低越好 | $594.0K | $542.2M |
| 股东权益账面价值 | $154.5M | $2.1B |
| 总资产 | $295.8M | $2.9B |
| 负债/权益比越低杠杆越低 | 0.00× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资IBEXRGEN
| Q4 25 | $15.5M | $767.6M | ||
| Q3 25 | $22.7M | $748.7M | ||
| Q2 25 | $15.3M | $708.9M | ||
| Q1 25 | $13.0M | $697.2M | ||
| Q4 24 | $20.2M | $757.4M | ||
| Q3 24 | $62.3M | $784.0M | ||
| Q2 24 | $62.7M | $809.1M | ||
| Q1 24 | $50.7M | $780.6M |
总债务IBEXRGEN
| Q4 25 | $594.0K | $542.2M | ||
| Q3 25 | $726.0K | $537.9M | ||
| Q2 25 | $796.0K | — | ||
| Q1 25 | $735.0K | — | ||
| Q4 24 | $695.0K | $525.6M | ||
| Q3 24 | $802.0K | — | ||
| Q2 24 | $867.0K | — | ||
| Q1 24 | $820.0K | — |
股东权益IBEXRGEN
| Q4 25 | $154.5M | $2.1B | ||
| Q3 25 | $143.6M | $2.1B | ||
| Q2 25 | $134.3M | $2.1B | ||
| Q1 25 | $124.2M | $2.0B | ||
| Q4 24 | $108.9M | $2.0B | ||
| Q3 24 | $171.1M | $2.0B | ||
| Q2 24 | $165.8M | $2.0B | ||
| Q1 24 | $159.3M | $2.0B |
总资产IBEXRGEN
| Q4 25 | $295.8M | $2.9B | ||
| Q3 25 | $283.9M | $2.9B | ||
| Q2 25 | $273.2M | $2.9B | ||
| Q1 25 | $274.7M | $2.9B | ||
| Q4 24 | $272.5M | $2.8B | ||
| Q3 24 | $306.3M | $2.8B | ||
| Q2 24 | $293.9M | $2.9B | ||
| Q1 24 | $289.6M | $2.8B |
负债/权益比IBEXRGEN
| Q4 25 | 0.00× | 0.26× | ||
| Q3 25 | 0.01× | 0.26× | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | 0.27× | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.6M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-5.1M | $17.6M |
| 自由现金流率自由现金流/营收 | -3.1% | 8.9% |
| 资本支出强度资本支出/营收 | 7.1% | 4.1% |
| 现金转化率经营现金流/净利润 | 0.54× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $29.3M | $93.9M |
8季度趋势，按日历期对齐
经营现金流IBEXRGEN
| Q4 25 | $6.6M | $25.7M | ||
| Q3 25 | $15.7M | $48.1M | ||
| Q2 25 | $27.9M | $28.6M | ||
| Q1 25 | $8.8M | $15.0M | ||
| Q4 24 | $1.1M | $39.2M | ||
| Q3 24 | $7.8M | $49.3M | ||
| Q2 24 | $17.4M | $42.2M | ||
| Q1 24 | $11.4M | $44.7M |
自由现金流IBEXRGEN
| Q4 25 | $-5.1M | $17.6M | ||
| Q3 25 | $8.0M | $43.4M | ||
| Q2 25 | $22.8M | $21.5M | ||
| Q1 25 | $3.6M | $11.4M | ||
| Q4 24 | $-3.2M | $33.6M | ||
| Q3 24 | $4.1M | $42.3M | ||
| Q2 24 | $15.2M | $37.4M | ||
| Q1 24 | $9.7M | $36.4M |
自由现金流率IBEXRGEN
| Q4 25 | -3.1% | 8.9% | ||
| Q3 25 | 5.3% | 23.0% | ||
| Q2 25 | 15.5% | 11.8% | ||
| Q1 25 | 2.5% | 6.8% | ||
| Q4 24 | -2.3% | 19.3% | ||
| Q3 24 | 3.2% | 27.3% | ||
| Q2 24 | 12.2% | 24.3% | ||
| Q1 24 | 7.7% | 24.0% |
资本支出强度IBEXRGEN
| Q4 25 | 7.1% | 4.1% | ||
| Q3 25 | 5.1% | 2.5% | ||
| Q2 25 | 3.5% | 3.9% | ||
| Q1 25 | 3.7% | 2.1% | ||
| Q4 24 | 3.1% | 3.2% | ||
| Q3 24 | 2.8% | 4.5% | ||
| Q2 24 | 1.8% | 3.1% | ||
| Q1 24 | 1.3% | 5.5% |
现金转化率IBEXRGEN
| Q4 25 | 0.54× | 1.93× | ||
| Q3 25 | 1.30× | 3.23× | ||
| Q2 25 | 2.91× | 1.92× | ||
| Q1 25 | 0.84× | 2.57× | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.77× | 12.70× | ||
| Q1 24 | 1.11× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBEX
| Transferred Over Time | $147.1M | 90% |
| Transferred At Point In Time | $17.1M | 10% |
RGEN
暂无分部数据
